Company profile: Elsie Biotechnologies
1.1 - Company Overview
Company description
- Provider of RNA therapeutics and oligonucleotide discovery technologies, including a proprietary ultra-high throughput platform that evaluates oligonucleotide chemical space to optimize therapeutic candidates for activity, toxicity, and delivery, and P(V) chemistry technologies with novel reagents and processes to synthesize diverse oligonucleotide therapeutics with complete synthetic control.
Products and services
- Oligonucleotide Therapeutics: Next-generation RNA drug candidates discovered via the platform, optimized for activity, toxicity, and delivery to address diseases historically considered undruggable
- Discovery Platform: Proprietary ultra-high throughput process that evaluates oligonucleotide chemical space to optimize therapeutic candidates for activity, toxicity, and delivery across RNA therapeutics
- P(V) Chemistry Technologies: Novel suite of reagents and processes used to synthesize diverse oligonucleotide therapeutics with complete synthetic control
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Elsie Biotechnologies
Editas Medicine
HQ: United States
Website
- Description: Provider of clinical-stage genome editing medicines and a CRISPR gene editing platform, including Reni-cel for severe sickle cell disease and transfusion-dependent beta thalassemia (editing CD34+ cells at HBG1/HBG2 promoters), EDIT-101 for Leber congenital amaurosis 10 (repairing the IVS26 CEP290 allele), and ex vivo and in vivo gene editing medicines for ocular, blood diseases, and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Editas Medicine company profile →
Egen
HQ: United States
Website
- Description: Provider of safe, efficient delivery systems for the manufacture of nucleic acid and anti-cancer drugs and for creating products to treat human diseases, offering synthetic biocompatible delivery vehicles to deliver therapeutic genes, inhibitory RNA (siRNA & shRNA), and small molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Egen company profile →
4D Molecular Therapeutics
HQ: United States
Website
- Description: Provider of transformative gene therapeutic products enabled by a Therapeutic Vector Evolution Platform using directed evolution to create customized viral vectors for targeted delivery. Offers R100 for retinal diseases, A101 for aerosol lung delivery, and C102 for intravenous heart muscle delivery, plus a product design & development engine and in-house GMP manufacturing and IND-enabling technical operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4D Molecular Therapeutics company profile →
Kriya Therapeutics
HQ: United States
Website
- Description: Provider of gene therapies for ophthalmology, neurology, and metabolic diseases, including KRIYA-825 for geographic atrophy (inhibiting C3/C5; one-time suprachoroidal), KRIYA-586 for thyroid eye disease (blocking IGF1 receptor), KRIYA-839 for diabetes (insulin and glucokinase), KRIYA-497 for NASH (FGF21), and KRIYA-748 and KRIYA-382 for trigeminal neuralgia and focal epilepsy via chemogenetically gated ion channels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kriya Therapeutics company profile →
Prevail Therapeutics
HQ: United States
Website
- Description: Provider of novel AAV9-based gene therapies for neurodegenerative diseases. Offerings include PR001, delivering a healthy GBA1 gene to correct lysosomal dysfunction in Parkinson's disease with GBA1 mutations and Type 1 Gaucher disease, and PR006, delivering a healthy GRN gene to raise progranulin for frontotemporal dementia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prevail Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Elsie Biotechnologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Elsie Biotechnologies
2.2 - Growth funds investing in similar companies to Elsie Biotechnologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Elsie Biotechnologies
4.2 - Public trading comparable groups for Elsie Biotechnologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →